2-乙烯-吗啉 | 98548-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 2-乙烯-吗啉
• 英文名称: 2-Vinylmorpholine
• 英文别名: 2-ethenylmorpholine
• CAS: 98548-70-0
• 化学式: C₆H₁₁NO
• mdl: MFCD09701960
• 分子量: 113.16
• InChiKey: GYEQLVFBKDAMHD-UHFFFAOYSA-N

物化性质

• 沸点：
  162.6±25.0 °C(Predicted)
• 密度：
  0.989±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES<br/>[FR] COMPOSÉS SPIROCYCLIQUES ET LEUR UTILISATION COMME AGENTS THÉRAPEUTIQUES ET SONDES DE DIAGNOSTIC
  申请人：UNIV BASEL

  公开号：WO2011114275A1

  公开（公告）日：2011-09-22

  The invention relates to new triazines (G = Q = U are N), pyrimidines (two out of G, Q and U are N), and pyridopyrimidines (one of G and U together with R2 forms an anullated pyridine ring) of formula (I) carrying a spirocyclic substituent, wherein E1 is CR4 or N; X1 is CHR4, CH2CH2, NR4, NR4→0, or O; and the other substituents are as defined in the specification. The compounds inhibit phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), DNA-PK and ATM kinase, and may be used as therapeutic agents or diagnostic probes. The invention also relates to methods of using the compounds for treatment of associated pathological conditions.

  本发明涉及新的三嗪类化合物（其中G = Q = U为N）、嘧啶类化合物（其中G、Q和U中的两个为N）和吡啶嘧啶类化合物（其中G和U中的一个与R2共同形成一个环状吡啶环），它们都带有一个螺环取代基，化学式为（I）。其中，E1为CR4或N；X1为CHR4、CH2CH2、NR4、NR4→0或O；其他取代基如规范中所定义。这些化合物能够抑制磷脂酰肌醇3-激酶（PI3K）、哺乳动物雷帕霉素靶蛋白酶（mTOR）、DNA-PK和ATM激酶，并可用作治疗剂或诊断探针。本发明还涉及使用这些化合物治疗相关病理条件的方法。
• SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES
  申请人：Cmiljanovic Vladimir

  公开号：US20130040934A1

  公开（公告）日：2013-02-14

  The invention relates to new triazines (G=Q=U are N), pyrimidines (two out of G, Q and U are N), and pyridopyrimidines (one of G and U together with R2 forms an anullated pyridine ring) of formula (I) carrying a spirocyclic substituent, wherein E 1 is CR 4 or N; X 1 is CHR 4 , CH 2 CH 2 , NR 4 , NR4→0, or O; and the other substituents are as defined in the specification. The compounds inhibit phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), DNA-PK and ATM kinase, and may be used as therapeutic agents or diagnostic probes. The invention also relates to methods of using the compounds for treatment of associated pathological conditions.

  该发明涉及具有螺环取代基的新三嗪类化合物（其中G=Q=U为N）、嘧啶类化合物（其中G、Q和U中的两个为N）和吡啶嘧啶类化合物（其中G和U中的一个与R2一起形成一个环状吡啶环）的化学式（I），其中E1为CR4或N；X1为CHR4、CH2CH2、NR4、NR4→0或O；其他取代基如规范中定义。这些化合物抑制磷脂酰肌醇3-激酶（PI3K）、哺乳动物雷帕霉素靶蛋白（mTOR）、DNA-PK和ATM激酶，并可用作治疗剂或诊断探针。该发明还涉及使用这些化合物治疗相关病理条件的方法。
• Structure having balanced pH profile
  申请人：Wallajapet Raj Ramaswami Palani

  公开号：US20060135641A1

  公开（公告）日：2006-06-22

  Disclosed is an absorbent structure comprising an acidic or basic water-swellable, water-insoluble polymer, a basic or acidic second material, and, optionally, a buffering agent, wherein the absorbent structure exhibits desirable absorbent properties. Specifically, the present invention relates to an absorbent structure having the ability to absorb a large quantity of liquid while maintaining a substantially desired and balanced pH profile on or along the upper surface of the absorbent structure. The absorbent structure is useful in disposable absorbent products, such as those disposable absorbent products that are used to absorb body liquid.

  揭示了一种吸收结构，包括酸性或碱性的水膨胀、水不溶性聚合物，一种碱性或酸性的第二材料，以及可选的缓冲剂，其中该吸收结构表现出理想的吸收性能。具体而言，本发明涉及一种吸收结构，具有吸收大量液体的能力，同时在吸收结构的上表面或沿着上表面保持基本理想和平衡的pH值。该吸收结构适用于一次性吸收性产品，例如用于吸收体液的一次性吸收性产品。
• Percutaneous absorption-type pharmaceutical preparation
  申请人：Inosaka Keigo

  公开号：US20060275354A1

  公开（公告）日：2006-12-07

  A stable percutaneous absorption-type pharmaceutical preparation for percutaneous administration of drugs except for selegiline and selegiline hydrochloride, which does not suffer a decrease in the cohesive force of the adhesive layer therein even in the presence of sweat components due to perspiration during wear and which is free from cohesive failure and resultant adhesive remaining when stripped off. A percutaneous absorption-type pharmaceutical preparation which comprises: a support; and an adhesive layer containing an adhesive, a metal chloride and a percutaneously-absorptive drug except for selegiline and selegiline hydrochloride, wherein the adhesive layer is subjected to a crosslinking treatment.

  一种稳定的经皮吸收型药物制剂，用于除去赛洛吉林和赛洛吉林盐酸盐以外的药物的经皮给药，即使在穿戴过程中由于出汗而存在汗液成分时也不会减少粘合层的粘合力，并且在剥离时不会出现内聚力失效和残留粘合剂。一种经皮吸收型药物制剂，包括：一种支撑物；和一个含有粘合剂、金属氯化物和除赛洛吉林和赛洛吉林盐酸盐之外的经皮吸收药物的粘合层，其中粘合层经过交联处理。
• Production method of nicotine transdermal preparation
  申请人：Ninomiya Kazuhisa

  公开号：US20070026055A1

  公开（公告）日：2007-02-01

  The present invention provides a production method of a nicotine transdermal preparation, which includes a step of forming, on a support, an adhesive layer containing an adhesive and a liquid ingredient compatible with the adhesive, and a step of impregnating the adhesive layer with nicotine by continuously applying nicotine to the adhesive layer. The production method of the present invention permits direct application of nicotine to the adhesive layer, which is not possible by conventional techniques, and the nicotine transdermal preparation provided by the method is associated with less physical skin irritation on peeling off and affords a good feeling during adhesion.

  本发明提供了一种尼古丁经皮制剂的生产方法，包括在支撑物上形成一个含有粘合剂和与粘合剂相容的液体成分的粘合层的步骤，以及通过持续向粘合层施加尼古丁来浸渍粘合层的步骤。本发明的生产方法允许将尼古丁直接应用于粘合层，这是传统技术所无法实现的，而该方法提供的尼古丁经皮制剂在剥离时与较少的皮肤刺激相关，并在贴合过程中提供良好的感觉。